NSEAgreements9 Sept 2026 · 9 Sept 2026, 05:19 pm
Agreements
Eris Lifesciences Limited · ERIS
✦ AI SummaryDebt Restruc.
Eris Lifesciences Limited has informed the Exchange about Loan Agreement with Axis Bank Limited for a term loan amounting to ₹45,00,00,000/- (Rupees Forty Five Crores Only). The loan will not impact the expected Net Debt figure at the end of the quarter.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk3/10
Balance Sheet Risk6/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Eris Lifesciences Limited has informed the Exchange about Loan Agreement
Attachments (1)
📄pdf
Download →
ERIS_09092026170436_intimationsigned.pdf
View document text
Date: 09 September 2026
To To
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza
Dalal Street Bandra Kurla Complex
Mumbai- 400001 Bandra (E)
Mumbai-400051
Security Code: 540596 Symbol: ERIS
SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF
SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)
Dear Sir/Madam,
We would like to inform that the Company has entered into an agreement to avail a term loan amounting to
₹45,00,00,000/- (Rupees Forty Five Crores Only) from Axis Bank Limited. Being a matter of routine financials
adjustment, it will not impact on the expected Net Debt figure at the end of the quarter.
In accordance with requirement of regulation 30 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 read with Para B of Part A of Schedule III and SEBI Master Circular
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, details attached herein shall be taken on
record.
Thanking You,
For Eris Lifesciences Limited
Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493
Encl: As above
Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course
of business, revision(s) or amendment(s) and termination(s) thereof:
Sr. No. Particulars Details
1. name(s) of parties with whom the agreement is Axis Bank Limited (“Bank/Axis”) and Eris
entered Lifesciences Limited (“Company”)
2. purpose of entering into the agreement The Company has drawn down a term loan
amounting to ₹45,00,00,000/- (Rupees Forty Five
Crores Only) from Axis Bank Limited to meet other
liabilities
3. Size of agreement ₹ 45,00,00,000/- (Rupees Forty Five Crores Only)
4. shareholding, if any, in the entity with whom the NIL
agreement is executed
5. significant terms of the agreement (in brief) special NA
rights like right to appoint directors, first right to
share subscription in case of issuance of shares,
right to restrict any change in capital structure etc.
6. whether, the said parties are related to NA
promoter/promoter group/ group companies in any
manner. If yes, nature of relationship
7. whether the transaction would fall within related NA
party transactions? If yes, whether the same is done
at “arm’s length”
8. in case of issuance of shares to the parties, details NA
of issue price, class of shares issued
9. in case of loan agreements:
details of lender/borrower, Axis Bank Limited
nature of the loan, Term Loan
total amount of loan granted/taken, ₹ 45,00,00,000/- (Rupees Sixty Four Crores forty
Lakhs Only)
total amount outstanding, Term Loan: 155.77 Crores
Working Capital Loan: 55 Crores
date of execution of the loan The term loan agreement is executed on 09
agreement/sanction letter September 2026.
details of the security provided to the lenders / The Bank willl have a charge on the Brands of the
by the borrowers for such loan or in case Company.
outstanding loans lent to a party or borrowed
from a party become material on a cumulative
basis;
10. any other disclosures related to such agreements, NA
viz., details of nominee on the board of directors of
the listed entity, potential conflict of interest arising
out of such agreements, etc.
11. in case of termination or amendment of agreement, NA
listed entity shall disclose additional details to the
stock exchange(s):
i. name of parties to the agreement;
ii. nature of the agreement;
iii. date of execution of the agreement;
iv. details of amendment and impact thereof or
reasons of termination and impact thereof.